Dr Lisa Ebert (B.Sc. (Hons), PhD) is a clinically-oriented cancer research scientist, with a particular interest in immunology and cancer immunotherapy.
She completed her PhD at the University of Adelaide, before undertaking post-doctoral research at the University of Bern (Switzerland) and the Ludwig Institute for Cancer Research (Melbourne). During this time, she developed particular experience in human immunology, cancer cell biology, multi-parameter flow cytometry and immune monitoring of cancer immunotherapy clinical trials.
She is now a Senior Research Fellow at the Centre for Cancer Biology (CCB) - an alliance between UniSA and SA Pathology. Her research is aimed at understanding interactions between cancer cells and the immune... Read more
About me
Dr Lisa Ebert (B.Sc. (Hons), PhD) is a clinically-oriented cancer research scientist, with a particular interest in immunology and cancer immunotherapy.
She completed her PhD at the University of Adelaide, before undertaking post-doctoral research at the University of Bern (Switzerland) and the Ludwig Institute for Cancer Research (Melbourne). During this time, she developed particular experience in human immunology, cancer cell biology, multi-parameter flow cytometry and immune monitoring of cancer immunotherapy clinical trials.
She is now a Senior Research Fellow at the Centre for Cancer Biology (CCB) - an alliance between UniSA and SA Pathology. Her research is aimed at understanding interactions between cancer cells and the immune system, and using this knowledge to improve cancer treatment. Recent projects have focused on identifying molecules that regulate blood vessel development in melanoma, developing new immunotherapy approaches for treating glioblastoma (brain tumours) and optimising the therapeutic efficacy of checkpoint inhibitors in melanoma.
Dr Ebert is based within the Translational Oncology research group headed by Professor Michael Brown. She also collaborates closely with the Vascular Biology and Cell Trafficking group headed by A/Prof Claudine Bonder. She has co-authored numerous papers in the fields of immunology and cancer - please click on the green ORCID ID badge to the right for details. She currently holds research grants from the Royal Adelaide Hospital Research Foundation and Neurosurgical Research Foundation, and supervises several Honours, Masters and PhD students.
Research
Excludes commercial-in-confidence projects.
Desmoglein-2; an unsuspected regulator of melanoma, NHMRC - Project Grant, 01/01/2019 - 31/12/2022
Development of a new therapy for glioblastoma based on chimeric antigen receptor (CAR)-T cells, Tour de Cure Ltd, 01/01/2021 - 31/12/2022
Checkpoint blockade immunotherapy in melanoma: getting tumour-killing T cells to their site of action, Royal Adelaide Hospital, 01/01/2016 - 31/03/2017
Validation of a novel therapeutic target in multiple myeloma, Royal Adelaide Hospital, 01/01/2016 - 31/03/2017
Research
Research outputs for the last seven years are shown below. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2022 |
Open access
2
2
12
|
| 2022 |
Open access
5
|
| 2021 |
Open access
11
10
3
|
| 2021 |
Open access
3
2
5
|
| 2021 |
Open access
2
2
2
|
| 2021 |
Open access
7
4
8
|
| 2020 |
Open access
14
12
5
|
| 2020 |
Open access
10
7
3
|
| 2020 |
Open access
11
10
9
|
| 2019 |
Open access
21
21
5
|
| 2019 |
16
19
2
|
| 2019 |
Open access
5
5
|
| 2019 |
64
62
9
|
| 2018 |
18
17
5
|
| 2017 |
10
|
| 2017 |
Open access
21
21
3
|
| 2016 |
Open access
22
23
|
| 2016 |
Open access
31
31
2
|
| 2015 |
Open access
12
12
4
|
| 2015 |
Open access
52
50
|
| 2013 |
4
4
1
|
| 2012 |
5
3
|
| 2012 |
Open access
44
44
6
|
External engagement & recognition
| Organisation | Country |
|---|---|
| Austin Health | AUSTRALIA |
| CSL Limited | AUSTRALIA |
| Flinders University | AUSTRALIA |
| Hebrew University | MEXICO |
| La Trobe University | AUSTRALIA |
| Ludwig Institute for Cancer Research | AUSTRALIA |
| Mashhad University of Medical Sciences | IRAN |
| Miltenyi Biotec | GERMANY |
| Peter MacCallum Cancer Centre | AUSTRALIA |
| Queensland University of Technology | AUSTRALIA |
| Royal Adelaide Hospital | AUSTRALIA |
| South Australian Health and Medical Research Institute (SAHMRI) | AUSTRALIA |
| University of Adelaide | AUSTRALIA |
| University of California | UNITED STATES |
| University of New South Wales | AUSTRALIA |
| University of South Australia | AUSTRALIA |
| Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| Finding out how well chimeric antigen receptor (CAR)-T cells kill brain tumour cells | Current |
| Targeting cancer cell invasion for new personalised therapeutic approaches against glioblastoma | Current |
| Targeting the tumour vasculature in melanoma for a more effective immune response and improved survival | Current |
| Optimising CAR T cell manufacturing for solid cancers | Completed |
| The role of platelets in vasculogenic mimicry | Completed |
| Vasculogenic mimicry: regulation and function in melanoma | Completed |
